Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated

Status Completed

Clinical Trial Summary

Artemether-lumefantrine has been used in Tanzania as first-line treatment for uncomplicated malaria since 2007. Nonetheless, a report of increased proportion of patients with parasitaemia on day 1 following treatment with artemisinin based combination therapies has emerged from Kenya. Similarly, resistance against artemisinins has been confirmed in South-East Asia and it can spread to Africa. Therefore, the purpose of this study was to assess the efficacy of Artemether-lumefantrine for the treatment of uncomplicated malaria among children after five years of wide scale use of the drug in Tanzania.

Clinical Trial Description

Artemisinin based combination therapies (ACTs) are currently recommended by the World Health Organization (WHO) as first-line treatment for uncomplicated malaria in all malaria endemic countries including Tanzania, that adopted the policy in 2007. ACTs have proven to be highly efficacious in different parts of the world with different malaria endemicity. Artemisinins clear asexual parasites rapidly and they are also potent against P. falciparum gametocytes, hence reducing disease transmission and spread of drug resistance. Nonetheless, a report in Kenya shows an increase in proportion of patients with parasitaemia on day 1. Most recently, resistance against artemisinins has been confirmed in four countries of South-East Asia, and it may spread to Africa.

In order to safeguard ACTs life span, WHO recommends all suspected malaria cases to be confirmed with parasitological diagnosis, followed by prompt treatment with effective antimalarials. It also emphasizes on the need to conduct efficacy studies for the first and second line antimalarial treatments after every two years so as to be able to detect resistance early on its course. Therefore, based on this notion, this study aimed to assess the therapeutic efficacy of Artemether/Lumefantrine among children with uncomplicated falciparum malaria in Bagamoyo district, five years after its wide scale use in Tanzania. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02089841
Study type	Interventional
Source	Muhimbili University of Health and Allied Sciences
Contact
Status	Completed
Phase	Phase 4
Start date	May 2012
Completion date	August 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04577066` - Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.	Phase 1/Phase 2
Completed	`NCT01883609` - A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S	Phase 1/Phase 2
Completed	`NCT00593398` - Malarial Immunity in Pregnant Cameroonian Women
Completed	`NCT01659281` - Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand	N/A
Completed	`NCT00074841` - Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India	Phase 2/Phase 3
Recruiting	`NCT04416945` - Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic	N/A
Completed	`NCT00314899` - Fetal Immunity to Falciparum Malaria
Completed	`NCT02867059` - SJ733 Induced Blood Stage Malaria Challenge Study	Phase 1
Completed	`NCT00701961` - Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy	Phase 2/Phase 3
Completed	`NCT00338520` - Hyperphenylalaninemia in Cerebral Malaria	N/A
Completed	`NCT00707200` - The Cytoadherence in Pediatric Malaria (CPM) Study	N/A
Completed	`NCT00393757` - Malaria Transmission and Immunity in Highland Kenya
Completed	`NCT03783299` - Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic	Phase 4
Completed	`NCT02614404` - Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria	Phase 1
Completed	`NCT00358332` - Phase I Pediatric FMP2.1/AS02A Trial in Mali	Phase 1
Completed	`NCT00730782` - Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers	Phase 1
Completed	`NCT00349713` - FMP2.1 Trial in Bandiagara, Mali	Phase 1
Recruiting	`NCT05052502` - Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand	N/A
Completed	`NCT04093765` - Mass Screening and Treatment for Reduction of Falciparum Malaria	N/A
Completed	`NCT03764527` - Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. — ALE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms